Spleen response during RUX treatment
PET-MF, PPV-MF, disease subentities, PMF
SPLEEN
Figure Spleen length below costal margin by palpation during the course of the trial. Median with lower and upper quadrants (The extent of spleen length reduction among the three disease subentities (PMF, PPV-MF, and PET-MF) was similar, with the largest reduction observed in patients with PPV-MF and the smallest in patients with PET-MF, but the effect was dose dependent, with a more pronounced reduction observed with 40 mg/day RUX compared with 20 mg/day or 10 mg/day.Spleen assessment by abdominal ultrasound was performed in 75.7% of cases at baseline. While spleen volume was only rarely reported, spleen length by ultrasound was frequently reported, with a median length of 18.5 cm. Spleen length by ultrasound after 2 months of RUX therapy was reported as 16.2 cm (median change of –2.0 cm vs baseline). The extent of spleen length reduction by ultrasound was again highest in the PPV-MF group and lowest in the PET-MF group, and dose dependent, with the most pronounced dose reduction seen with 40 mg/day RUX.Interestingly, correlation between spleen size measured by palpation (values BCM) vs spleen length by ultrasound was accurate (Fig. Differences in spleen length measurement from baseline to last post-baseline visit by ultrasoundPearson correlation between spleen size measured by palpation vs in ultrasound (